
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc. is well-positioned for growth in the metabolic therapeutics sector, as evidenced by the substantial 587% increase in prescriptions for GLP-1 drugs from 2019 to 2024, highlighting a significant shift in treatment paradigms for obesity and type 2 diabetes. The company anticipates sufficient manufacturing capacity to support its upcoming first-in-human Phase 1 trial, suggesting a streamlined pathway to scalability as their technologies evolve. Furthermore, data from the REMAIN-1 trial indicates the potential for Revita to achieve a peak penetration of 2%, bolstered by favorable outcomes in blood glucose control and improvements in lipid profiles, which may enhance Fractyl Health’s competitive positioning in the market.
Bears say
Fractyl Health Inc faces significant challenges in its financial outlook primarily due to high cash burn rates that may escalate with the expansion of development and commercial programs, and uncertainty regarding securing sufficient capital for ongoing projects like the Revita and Rejuva platforms. Additionally, the gradual loss of β-cell function in patients with type 2 diabetes presents a persistent obstacle to achieving durable therapeutic outcomes, as it necessitates complex and effective interventions to enhance insulin levels. Research indicates potential limitations in the efficacy of their approaches compared to existing pharmacological treatments, which may impact the company’s competitive standing and further jeopardize its financial viability.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares